---
title: "iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288413843.md"
description: "IBIO-600 is a promising long-acting anti-myostatin monoclonal antibody that aims to preserve muscle and enhance body composition. It has been identified as a potential best-in-class candidate in its category."
datetime: "2026-06-02T11:02:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288413843.md)
  - [en](https://longbridge.com/en/news/288413843.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288413843.md)
generator: "portal-rs"
---

# iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

IBIO-600 is a promising long-acting anti-myostatin monoclonal antibody that aims to preserve muscle and enhance body composition. It has been identified as a potential best-in-class candidate in its category.

### Related Stocks

- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)

## Related News & Research

- [Analyst Warns of Significant Clinical and Regulatory Risks Facing Ibio Inc’s Drug Pipeline](https://longbridge.com/en/news/297478349.md)
- [iBio announces annual shareholder meeting](https://longbridge.com/en/news/298071487.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)
- [iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000](https://longbridge.com/en/news/297313027.md)
- [ITX: Record revenue and break-even EBITDA achieved on strong detergent ingredient growth](https://longbridge.com/en/news/298268381.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**